Debio 1347

Next Previous
Drug Profile

Debio 1347

Alternative Names: CH 5183284; Debio1347; FF 284

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Debiopharm
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Signal transduction pathway inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 14 Nov 2017 Debio 1347 receives Orphan Drug status for Biliary cancer in European Union
  • 10 Nov 2017 Phase-I/II clinical trials in Breast cancer (Combination therapy; Metastatic disease) in USA (PO) (NCT03344536)
  • 02 Jun 2017 Efficacy, adverse events, pharmacokinetics data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top